Clobac Powder for Suspension
Cefaclor
125mg/5ml
Opsonin Pharma Limited
| Pack size | 100ml bot |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 180.00 AED |
Available as:
Indications
Clobac Powder for Suspension is used for:
Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis, Tonsillitis
Adult Dose
Oral
Capsules/Tablets
Lower Respiratory Tract Infections
Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes
250-500 mg 8 hourly
Otitis Media
Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes
Capsules: 250-500 mg 8 hourly
Uncomplicated Skin and Skin Structure Infections
Skin and skin structure infections cause by Staphylococcus aureus and Streptococcus pyogenes
250-500 mg PO 8 hourly
Extended-release tablets: 375 mg PO 12 hourly for 7-10 days
Urinary Tract Infections
Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp, and coagulase-negative staphylococci
250-500 mg 8 hourly
Bronchitis
Acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding beta-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae
Extended-release tablets: 500 mg 12 hourlyr for 7 days
Pharyngitis and Tonsillitis
Pharyngitis and tonsillitis due to Streptococcus pyogenes
Capsules/Tablets: 250-500 mg 8 hourly
Extended-release tablets: 750 mg PO 12 hourly for 10 days
Child Dose
Oral
Urinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media
Child: PO 20–40 mg/kg/day, max 1 g/day 12 hourly
Child 1-5 yr: 125 mg tid,
Child >5 yr: 250 mg tid.
Child 12–17 years: 500 mg tid; maximum 4 g per day
Extended-release tablets:
Child 12–17 years: 375 mg every 12 hours
Suspension & Paediatric Drops:
1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d
1 year - 5 years 5 ml t.i.d. 1.25 ml t.i.d
over 5 years 10 ml t.i.d 2.5 ml t.i.d
Renal Dose
Renal impairment: No dosage adjustments provided
Use caution
Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and
by 3/4 if <10 mL/min (high doses may cause CNS toxicity)
Administration
May be taken with or without food.
Oral Suspension Preparation
Add 106 mL (125-mg or 250-mg bottle) or 68 mL (375-mg bottle) of water in two portions to dry mixture
Shake well after each addition
Each 5 mL (~1 tsp) will contain 125 mg, 250 mg, and 375 mg of cefaclor depending on package size
Contra Indications
Known hypersensitivity to cephalosporins.
Precautions
Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria
Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy
Bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy
Clostridium difficile associated diarrhea (CDAD)
CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile
Pregnancy-Lactation
Pregnancy
No adequate and well-controlled studies in pregnant women
Because animal reproduction studies are not always predictive of human response, cefaclor should be used during pregnancy only if necessary
Lactation
Effect on nursing infants is unknown; exercise caution when cefaclor is administered to a nursing woman
Extended-release tablets
No studies in lactating women performed; small amounts of cefaclor (?0.21 mcg/mL) detected in human milk following administration (single 500-mg dose of cefaclor extended-release tablets)
Interactions
May enhance the nephrotoxic effect of aminoglycosides.
May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate.
Concomitant use w/ warfarin may increase prothrombin time.
Probenecid inhibits renal excretion of cefaclor.
Contraindicated (0)
Serious (4)
BCG vaccine live
cholera vaccine
microbiota oral
typhoid vaccine live
Adverse Effects
Side effects of Cefaclor :
1-10%
Diarrhea (3%),Increased transaminases (3%),Eosinophilia (2%),Moniliasis (2%),Vaginitis (2%),Rash (maculopapular, erythematous, or morbiliform) (1-2%)
<1%
Stevens-Johnson syndrome,Pseudomembranous colitis,Nausea,Vomiting,Anemia,Neutropenia,Jaundice
Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.
Mechanism of Action
Cefaclor binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It has bactericidal activity against gm-ve bacteria including E. coli, S. pneumoniae, N. gonorrhoea, P. mirabilis and H. influenzae.
Note
Clobac 125mg/5ml Powder for Suspension manufactured by Opsonin Pharma Limited. Its generic name is Cefaclor. Clobac is availble in Bangladesh.
Farmaco BD drug index information on Clobac Powder for Suspension is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.